“Emirates Drug” adopts the drug “Joselkomab” for the treatment of inflammatory intestinal diseases

The Emirates Drug Corporation has adopted new uses for “Guselkumab”, to become the second country in the world to adopt this innovative drug in the treatment of “Crohn” patients.

This dependence reflects the UAE’s commitment to providing the latest medical treatments and its advanced uses, and enhancing innovation in the field of health care.

This accreditation provides a new and innovative treatment option for patients who suffer from these immune diseases, which contributes positively to improving the quality of their lives, and confirms the UAE’s leadership in providing advanced health solutions. This decision also reflects the UAE’s commitment to accelerate the access of innovative treatments to patients, consolidate international cooperation in the health field, and ensure the sustainability of medical products at competitive prices.

The drug contributes to improving treatment opportunities for many patients in the UAE and the region in general, as “Joselkomab” is an important addition to enhancing the treatments available for chronic inflammatory intestinal disorders, as the drug after an accurate review of clinical data has proven its effectiveness in treating incurable conditions and alleviating the symptoms of inflammatory intestinal diseases.

Dr. Fatima Al -Kaabi, Director General of the Emirates Drug Corporation, said that this achievement reflects the success of the state’s pre -emptive policies in enhancing drug security and providing the latest treatment solutions for patients, explaining that the approval of this drug was made after a comprehensive review of clinical studies that showed his ability to treat incurable conditions, which makes it a value added to the available treatment options.

She added that the process of adopting medicines in the Emirates Drug Corporation is characterized by accuracy and inclusiveness, with the use of the latest technologies and simplified procedures to ensure the speed and accuracy of reviewing requests and decision -making, noting that this achievement is the fruit of the hard work and dedication that the work team exerts to achieve the vision of rational leadership in establishing the UAE’s position as a preferred destination for major international pharmaceutical companies.

She emphasized that this achievement reflects the strength of the partnerships established by the Emirates Drug Corporation with health authorities and international pharmaceutical companies, which resulted in simplifying organizational procedures and accelerating the wheel of medicine, as it is evidence of the rational government’s commitment to providing the latest treatments for community members through an advanced health system that keeps pace with the finest international standards.

Dr. Al -Kaabi explained that the Foundation succeeded in developing an integrated organizational environment for pharmaceutical and medical products, supported by a sustainable drug security strategy and the “Fast Track” system, as this approach contributed to accelerating the arrival of innovative treatments for patients while adhering to the highest safety and effective standards.